Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Feb 21, 2007

BG Medicine Commences Investigation for Biomarkers of Hepatotoxicity

  • BG Medicine reports that the FDA approved the first phase of the Liver Toxicity Biomarker Study (LTBS). This discovery project aims at finding biomarkers related to human hepatotoxicity in standard preclinical tests.

    It will be conducted under a CRADA with the FDA’s National Center for Toxicological Research (NCTR), as part of FDA’s Critical Path Initiative.

    The scientific advisory board will consist of seven pharmaceutical companies—Pfizer, Johnson & Johnson Pharmaceutical Research and Development, Mitsubishi Chemical Holdings, Orion, UCB, Sankyo, and Eisai—providing project funding.

    Additionally, Applied Biosystems will supply biomarker discovery systems based on mass spectrometry, including service, support, and in-kind contributions.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »